dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Poveda, Andres |
dc.contributor.author | Oaknin Benzaquen, Ana Mazaltob |
dc.contributor.author | Redondo Sanchez, Andres |
dc.contributor.author | Rubio, Maria Jesus |
dc.contributor.author | Guerra, Eva |
dc.contributor.author | Fariñas Madrid, Lorena |
dc.contributor.author | Rodriguez Freixinos, Victor |
dc.contributor.author | López-Reig, Raquel |
dc.date.accessioned | 2022-07-20T11:04:32Z |
dc.date.available | 2022-07-20T11:04:32Z |
dc.date.issued | 2022-02-12 |
dc.identifier.citation | Poveda A, Lopez-Reig R, Oaknin A, Redondo A, Rubio MJ, Guerra E, et al. Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. Cancers. 2022 Feb 12;14(4):915. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/7879 |
dc.description | Càncer d'endometri; Inestabilitat genòmica; Olaparib |
dc.description.sponsorship | This trial was sponsored by AstraZeneca and PharmaMar, including supply of the drugs used in this study. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;14(4) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.title | Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers14040915 |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.3390/cancers14040915 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Poveda A] Oncogynecologic Department, Initia Oncology, Hospital Quironsalud, Valencia, Spain. [Lopez-Reig R] Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia, Spain. IVO-CIPF Joint Research Unit of Cancer, Príncipe Felipe Research Center (CIPF), Valencia, Spain. [Oaknin A, Fariñas-Madrid L] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Redondo A] Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Universidad Autónoma de Madrid (UAM), Madrid, Spain. [Rubio MJ] Medical Oncology Department, Universitary Hospital Reina Sofia, Cordoba, Spain. [Guerra E] Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Rodriguez-Freixinos V] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada |
dc.identifier.pmid | 35205662 |
dc.identifier.wos | 000763155700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |